Department of Surgery, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden.
World J Surg. 2012 Jun;36(6):1389-94. doi: 10.1007/s00268-012-1430-6.
Germline mutations in the susceptibility genes RET, SDHB, SDHD, and VHL have been reported in 7.5-24% of patients with pheochromocytoma (Pheo) or paraganglioma (PGL) and sporadic presentation. The purpose of the present study was to establish population-based data on the frequency of germline mutations in patients with apparently sporadic Pheo or abdominal PGL in Western Sweden.
From the Swedish National Cancer Registry, all patients with Pheo or PGL in Western Sweden (population 1.72 million) registered between 1958 and 2009 were identified (n = 256). Patients were characterized using register data, hospital records, and clinical interviews. All living patients with Pheo or abdominal PGL and sporadic presentation (n = 81) were invited to genetic screening; 71 patients accepted. Germline mutations were investigated by using direct sequencing for point mutations in RET, SDHB, SDHD, and VHL, and multiplex ligation-dependent probe amplification for gross deletions in SDHB, SDHC, SDHD, and VHL. Plasma or urinary metanephrines and/or urinary catecholamines were used for biochemical follow-up.
The prevalence of germline mutations was 5.6%. Mutations were only seen in RET (n = 1) and SDHB (n = 3). Notably, in the patients with SDHB mutations, no malignant phenotype was observed during a mean follow-up of 23.3 years.
The frequency of germline mutations in patients with apparently sporadic Pheo and abdominal PGL in Western Sweden was lower than in previous studies. Variations in reported frequencies of germline mutations in patients with clinically sporadic Pheo/PGL may reflect geographical differences or patient selection.
在散发性表现的嗜铬细胞瘤(Pheo)或副神经节瘤(PGL)患者中,已经报道了易感基因 RET、SDHB、SDHD 和 VHL 的种系突变,其发生率为 7.5-24%。本研究的目的是建立瑞典西部散发性 Pheo 或腹部 PGL 患者中种系突变的频率的基于人群的数据。
从瑞典国家癌症登记处,确定了 1958 年至 2009 年期间在瑞典西部登记的所有 Pheo 或 PGL 患者(人口 172 万)(n=256)。使用登记数据、医院记录和临床访谈对患者进行了特征描述。所有具有散发性表现的 Pheo 或腹部 PGL 且仍存活的患者(n=81)均被邀请进行遗传筛查;71 名患者接受了邀请。通过对 RET、SDHB、SDHD 和 VHL 的点突变进行直接测序,以及对 SDHB、SDHC、SDHD 和 VHL 的大片段缺失进行多重连接依赖性探针扩增,来检测种系突变。使用血浆或尿液间甲肾上腺素和/或尿液儿茶酚胺进行生化随访。
种系突变的患病率为 5.6%。突变仅见于 RET(n=1)和 SDHB(n=3)。值得注意的是,在具有 SDHB 突变的患者中,在平均 23.3 年的随访中没有观察到恶性表型。
在瑞典西部具有散发性表现的 Pheo 和腹部 PGL 患者中,种系突变的频率低于以前的研究。在具有临床散发性 Pheo/PGL 的患者中报道的种系突变频率的差异可能反映了地域差异或患者选择。